HealthEquity (NASDAQ:HQY) Rating Increased to Buy at Wall Street Zen

Wall Street Zen upgraded shares of HealthEquity (NASDAQ:HQY) from a hold rating to a buy rating in a research report sent to investors on Saturday morning.

Several other analysts have also recently weighed in on HQY. Citigroup reissued a “market outperform” rating on shares of HealthEquity in a research note on Monday, June 1st. KeyCorp reaffirmed an “overweight” rating on shares of HealthEquity in a research report on Tuesday, May 26th. Citizens Jmp lifted their price target on shares of HealthEquity from $110.00 to $111.00 and gave the company a “market outperform” rating in a research report on Monday, June 1st. BTIG Research upped their price objective on HealthEquity from $110.00 to $115.00 and gave the company a “buy” rating in a report on Friday, July 24th. Finally, Wells Fargo & Company set a $111.00 price objective on HealthEquity in a research report on Monday, June 1st. Eleven investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $110.93.

HealthEquity Stock Up 1.1%

NASDAQ HQY opened at $105.41 on Friday. The business’s fifty day simple moving average is $96.64 and its 200-day simple moving average is $87.20. The company has a quick ratio of 3.44, a current ratio of 3.44 and a debt-to-equity ratio of 0.46. The firm has a market cap of $8.81 billion, a PE ratio of 39.48, a P/E/G ratio of 1.77 and a beta of 0.21. HealthEquity has a 52 week low of $72.76 and a 52 week high of $107.62.

HealthEquity (NASDAQ:HQY) last announced its quarterly earnings data on Thursday, May 28th. The company reported $1.24 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.11 by $0.13. HealthEquity had a net margin of 17.25% and a return on equity of 14.75%. The firm had revenue of $354.64 million during the quarter, compared to analyst estimates of $352.02 million. The company’s quarterly revenue was up 7.2% compared to the same quarter last year. HealthEquity has set its FY 2027 guidance at 2.880-2.950 EPS. As a group, equities analysts anticipate that HealthEquity will post 3.92 earnings per share for the current year.

Insiders Place Their Bets

In other news, EVP Delano Ladd sold 7,500 shares of the stock in a transaction dated Thursday, May 28th. The shares were sold at an average price of $90.00, for a total transaction of $675,000.00. Following the sale, the executive vice president owned 91,141 shares of the company’s stock, valued at approximately $8,202,690. This represents a 7.60% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Gayle Furgurson Wellborn sold 2,439 shares of the firm’s stock in a transaction that occurred on Thursday, May 28th. The shares were sold at an average price of $90.00, for a total transaction of $219,510.00. Following the completion of the transaction, the director directly owned 19,733 shares of the company’s stock, valued at approximately $1,775,970. The trade was a 11.00% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 17,905 shares of company stock worth $1,651,280 over the last three months. Company insiders own 1.60% of the company’s stock.

Hedge Funds Weigh In On HealthEquity

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Acumen Wealth Advisors LLC purchased a new stake in shares of HealthEquity during the fourth quarter worth $27,000. Caitong International Asset Management Co. Ltd boosted its stake in shares of HealthEquity by 1,723.5% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 310 shares of the company’s stock valued at $28,000 after buying an additional 293 shares during the period. Aster Capital Management DIFC Ltd purchased a new position in HealthEquity in the fourth quarter worth approximately $28,000. Leonteq Securities AG lifted its position in shares of HealthEquity by 159.9% during the 1st quarter. Leonteq Securities AG now owns 382 shares of the company’s stock worth $32,000 after purchasing an additional 235 shares during the last quarter. Finally, Axiom Investment Management LLC purchased a new stake in HealthEquity during the 1st quarter worth about $33,000. Hedge funds and other institutional investors own 99.55% of the company’s stock.

About HealthEquity

HealthEquity, Inc (NASDAQ: HQY) is a leading administrator of consumer-directed health accounts and related benefit solutions in the United States. Founded in 2002 and headquartered in Draper, Utah, the company specializes in health savings accounts (HSAs) and offers complementary services such as flexible spending accounts (FSAs), health reimbursement arrangements (HRAs), COBRA administration and commuter benefits. Through its technology-driven platform, HealthEquity enables employers, health plans and individuals to streamline account management, improve cost transparency and encourage more informed healthcare spending.

Serving millions of members across all 50 states, HealthEquity leverages an open-architecture ecosystem that integrates with health plans, payroll providers and financial institutions.